Background: Gefitinib was approved by the Food and Drug Administration (FDA) of the
United States (US) for the treatment of advanced non-small cell carcinoma harboring …

Background Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and
histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of …

e18059 Background: Gefitinib is orally available, selective epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor used in patients with non-small cell lung cancer (NSCLC) …

Background: Gefitinib treatment has come to be recognized as the standard therapy for
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …

As a first-generation epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib was
approved by the US Food and Drug Administration for treatment of advanced non-small cell …

The efficacy of gefitinib for patients with non‐adenocarcinoma non‐small‐cell lung cancer
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …

Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and
have poor long-term prognosis. Gefitinib, a targeted therapy that prevents ATP binding in the …

Epidermal growth factor receptor (EGFR) gene mutations are frequent in lung cancer of
Asian ethnicity, female gender, non-smokers, and of adenocarcinoma histology. About 80 …

Purpose Gefitinib is safe for the treatment of non-small cell lung cancer (NSCLC), but some
patients experience toxicities and require dose reduction. The purpose of this study was to …

Objectives Gefitinib is a potent epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor and is a key drug for patients with EGFR mutation-positive advanced non-small cell …